Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,792 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetic Change Clear all

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Melanoma and Brain Metastases
Interventions: Dabrafenib 150 mg, Trametinib 2.0 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Solid Tumors
Interventions: REC-7735; Drug
Lead sponsor: Recursion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia

Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer
Interventions: PLX2853, Carboplatin; Drug
Lead sponsor: Opna Bio LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 5 more

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventions: Gilteritinib, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more

Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Interventions: Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor; Drug · Biological
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 38
States / cities: Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Brain Tumor, Cancer
Interventions: Zotiraciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 99 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Jacksonville, Florida • Bethesda, Maryland

Conditions: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Acute Myeloid (AML)
Interventions: gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine, MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more

Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
Interventions: Cytarabine, Filgrastim, Fludarabine, Fludarabine Phosphate, Ivosidenib, Idarubicin; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: APL-101, Osimertinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions: Tc99-PYP or Tc99-HDMP Scan; Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Dentatorubral-Pallidoluysian Atrophy
Interventions: nL-ATN1-002; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 17 Years to 17 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Weight Management, Diet Conditions, Dietary Recommendations, Overweight Management, Obesity
Interventions: Not listed
Lead sponsor: Interleukin Genetics, Inc.; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
Interventions: Tovorafenib, Tovorafenib Drug: Pimasertib; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more

Conditions: Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
Interventions: Not listed
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Seattle, Washington

Conditions: Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more

Conditions: Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
Interventions: Laboratory Biomarker Analysis, Selumetinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Cystic Fibrosis
Interventions: CFTR Modulators; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
Interventions: Tazemetostat; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 9 more

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX; Drug
Lead sponsor: Cardiff Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more

Conditions: Cystic Fibrosis
Interventions: SPL84, Placebo; Drug · Other
Lead sponsor: SpliSense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Boston, Massachusetts

Search by objective public record fields.

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

REC-7735 in Participants With Solid Tumors

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation

A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis